Adamis Pharmaceuticals (NASDAQ:ADMP) shares are trading lower on Monday after the company received a complete response letter from the FDA rejecting its ZIMHI.
Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company. It is focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy, and opioid overdose. Its SYMJEPI (epinephrine) Injection products are used in the emergency treatment of acute allergic reactions, including anaphylaxis.
Adamis is developing additional products, including a naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose, and other products for the treatment of asthma and COPD. Its subsidiary compounds sterile prescription drugs, and certain nonsterile drugs for use by hospitals, clinics, and surgery centers throughout the U.S.
Adamis Pharmaceuticals shares were trading down 38.96% at 42 cents at last check Monday. The stock has a 52-week high of $1.51 and a 52-week low of 27 cents.